Viekira Pak, a direct-acting antiviral medication indicated to treat Hepatitis C, has ben associated with liver injury, liver failure and reactivation of the Hepatitis B virus in co-infected patients. Filing a Viekira Pak lawsuit may be an option for individuals who suffered these life-threatening complications while using this medication.
The nationwide law firm of Bernstein Liebhard LLP is evaluating potential Viekira Pak lawsuits involving:
If you or a loved one experienced any of these issues while undergoing treatment with Viekira Pak, please call (888) 994-5118 to contact our attorneys today.
Viekira Pak s an oral, direct-acting antiviral approved to treat adults with genotype 1 chronic Hepatitis C. Its active ingredients include three direct acting antivirals, paritaprevir, ritonavir, and ombitasvir, as well as an antiviral called dasabuvir. Viekira Pak is sometimes used in conjunction with another Hepatitis C antiviral called ribavirin.
About 90% of patients taking Viekira Pak will be cured of Hepatitis C. However, the drug is not without risk. Since granting Viekira Pak approval in December 2014, the U.S. Food & Drug Administration (FDA) has issued a number of safety alerts for it and other direct-acting antivirals:
Viekira Pak patients who suffered serious liver injuries, liver failure or Hepatitis B virus reactivation may be entitled to compensation for injury-related damages, including:
Our attorneys are standing by to help patients and their families obtain the compensation they deserve. To learn more about filing a Viekira Pak lawsuit, please call (888) 994-5118 to arrange for a free, no-obligation review of your case.
Get the latest news and litigation updates about this case by following us on Facebook. Click the "Like" button below.